Literature DB >> 8033417

Co-expression of the CD45RA and CD45RO antigens on T lymphocytes in chronic arthritis.

K L Summers1, J L O'Donnell, D N Hart.   

Abstract

The site of T lymphocyte activation in chronic arthritis is unknown. Peripheral blood (PB) lymphocytes from chronic arthritis patients are in a 'naive' or non-activated state, as defined by expression of the CD45RA antigen and lack of HLA class II expression. In contrast, most synovial fluid (SF) T lymphocytes express a 'memory' or activated phenotype, as defined by the CD45RO antigen and high HLA class II expression. Following stimulation, naive cells lose CD45RA and gain CD45RO expression to become memory cells with a transitional stage of dual CD45RA, CD45RO antigen expression. To localize where this change in phenotype occurs we used dual colour immunofluorescence labelling to compare the percentage of dual CD45RA, CD45RO-positive T lymphocytes in PB and SF from chronic arthritic patients and from normal PB, assuming this population would be increased at the primary site of T lymphocyte activation. Expression of the intermediate and late activation marker, HLA-DR, was also analysed using dual colour immunofluorescence labelling. The percentage of dual positive T lymphocytes was similar between arthritic PB, SF, and normal PB, as was the density of both CD45RA and CD45RO antigens. Thus, CD45 isoform expression did not indicate where T lymphocytes were activated. However, we identified a previously unreported population of CD45RA+ CD45RO+ HLA-DR- T lymphocytes in arthritic and normal PB. In SF, this population was absent, but a substantial number of dual CD45RA, CD45RO-positive HLA-DR+ T lymphocytes were identified. This population would not be predicted by the current model of T lymphocyte activation. Division of T lymphocytes into functional groups on the basis of CD45 isoform expression is likely to be more complicated than previously thought. Based on our findings we propose an alternative model of T lymphocyte differentiation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8033417      PMCID: PMC1534775          DOI: 10.1111/j.1365-2249.1994.tb06576.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  26 in total

1.  Functional subsets of human helper-inducer cells defined by a new monoclonal antibody, UCHL1.

Authors:  S H Smith; M H Brown; D Rowe; R E Callard; P C Beverley
Journal:  Immunology       Date:  1986-05       Impact factor: 7.397

2.  Inhibition of natural killer-cell mediated cytolysis with monoclonal antibodies to restricted and non-restricted epitopes of the leucocyte common antigen.

Authors:  G C Starling; S E Davidson; J L McKenzie; D N Hart
Journal:  Immunology       Date:  1987-07       Impact factor: 7.397

3.  Increased helper inducer and decreased suppressor inducer phenotypes in the rheumatoid joint.

Authors:  H P Lasky; K Bauer; R M Pope
Journal:  Arthritis Rheum       Date:  1988-01

4.  Cellular events during memory T-cell activation in vitro: the UCHL1 (180,000 MW) determinant is newly synthesized after mitosis.

Authors:  A N Akbar; A Timms; G Janossy
Journal:  Immunology       Date:  1989-02       Impact factor: 7.397

5.  The isolation and characterization of the human helper inducer T cell subset.

Authors:  C Morimoto; N L Letvin; A W Boyd; M Hagan; H M Brown; M M Kornacki; S F Schlossman
Journal:  J Immunol       Date:  1985-06       Impact factor: 5.422

6.  Loss of CD45R and gain of UCHL1 reactivity is a feature of primed T cells.

Authors:  A N Akbar; L Terry; A Timms; P C Beverley; G Janossy
Journal:  J Immunol       Date:  1988-04-01       Impact factor: 5.422

7.  Dual CD45RA, CD45RO positive T-lymphocytes within rheumatoid arthritic joints.

Authors:  M D Hoy; J L O'Donnell; D N Hart
Journal:  Pathology       Date:  1993-04       Impact factor: 5.306

8.  Lymphocyte surface marker expression in rheumatic diseases: evidence for prior activation of lymphocytes in vivo.

Authors:  M D Smith; P J Roberts-Thomson
Journal:  Ann Rheum Dis       Date:  1990-02       Impact factor: 19.103

9.  Abnormal distribution of the helper-inducer and suppressor-inducer T-lymphocyte subsets in the rheumatoid joint.

Authors:  C Pitzalis; G Kingsley; J Murphy; G Panayi
Journal:  Clin Immunol Immunopathol       Date:  1987-11

10.  Ia determinants on stimulated human T lymphocytes. Occurrence on mitogen- and antigen-activated T cells.

Authors:  H S Ko; S M Fu; R J Winchester; D T Yu; H G Kunkel
Journal:  J Exp Med       Date:  1979-08-01       Impact factor: 14.307

View more
  12 in total

1.  Impaired CD4 and CD8 T cell phenotype and reduced chemokine secretion in recent-onset type 1 diabetic children.

Authors:  M Hedman; M Faresjö; S Axelsson; J Ludvigsson; R Casas
Journal:  Clin Exp Immunol       Date:  2008-09       Impact factor: 4.330

2.  Selective recruitment of CCR6-expressing cells by increased production of MIP-3 alpha in rheumatoid arthritis.

Authors:  T Matsui; T Akahoshi; R Namai; A Hashimoto; Y Kurihara; M Rana; A Nishimura; H Endo; H Kitasato; S Kawai; K Takagishi; H Kondo
Journal:  Clin Exp Immunol       Date:  2001-07       Impact factor: 4.330

3.  Endothelial cell and cAMP regulation of T-cell CD40 ligand: relevance of calcium/calmodulin-dependent kinase IV signalling.

Authors:  Christopher P Nielson; Denise Wingett
Journal:  Immunology       Date:  2002-04       Impact factor: 7.397

4.  Upregulation of CD4 on CD8+ T cells: CD4dimCD8bright T cells constitute an activated phenotype of CD8+ T cells.

Authors:  Y B Sullivan; A L Landay; J A Zack; S G Kitchen; L Al-Harthi
Journal:  Immunology       Date:  2001-07       Impact factor: 7.397

5.  Low expression of CD39(+) /CD45RA(+) on regulatory T cells (Treg ) cells in type 1 diabetic children in contrast to high expression of CD101(+) /CD129(+) on Treg cells in children with coeliac disease.

Authors:  K Åkesson; A Tompa; A Rydén; M Faresjö
Journal:  Clin Exp Immunol       Date:  2015-04       Impact factor: 4.330

6.  The role of innate cells is coupled to a Th1-polarized immune response in pediatric nonalcoholic steatohepatitis.

Authors:  Nazarena E Ferreyra Solari; María Eugenia Inzaugarat; Placida Baz; Elena De Matteo; Carol Lezama; Marcela Galoppo; Cristina Galoppo; Alejandra C Cherñavsky
Journal:  J Clin Immunol       Date:  2012-01-07       Impact factor: 8.317

7.  CD4 subsets (CD45RA/RO) exhibit differences in proliferative responses, IL-2 and gamma-interferon production during intravenous methylprednisolone treatment of multiple sclerosis.

Authors:  A D Crockard; M T Treacy; A G Droogan; S A Hawkins
Journal:  J Neurol       Date:  1996-06       Impact factor: 4.849

8.  Polyclonal T-cells express CD1a in Langerhans cell histiocytosis (LCH) lesions.

Authors:  Jennifer A West; Sharon L Olsen; Jenée M Mitchell; Ross E Priddle; Jennifer M Luke; Selma Olsson Akefeldt; Jan-Inge Henter; Christopher Turville; George Kannourakis
Journal:  PLoS One       Date:  2014-10-24       Impact factor: 3.240

9.  Clinical relevance of the severe abnormalities of the T cell compartment in septic shock patients.

Authors:  Jorge Monserrat; Raul de Pablo; Eduardo Reyes; David Díaz; Hugo Barcenilla; Manuel R Zapata; Antonio De la Hera; Alfredo Prieto; Melchor Alvarez-Mon
Journal:  Crit Care       Date:  2009-02-25       Impact factor: 9.097

10.  Multipotent adult progenitor cells induce regulatory T cells and promote their suppressive phenotype via TGFβ and monocyte-dependent mechanisms.

Authors:  Alice Valentin-Torres; Cora Day; Jennifer M Taggart; Nicholas Williams; Samantha R Stubblefield; Valerie D Roobrouck; Jelle Beyens; Anthony E Ting
Journal:  Sci Rep       Date:  2021-06-30       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.